Robert Shaw

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade.

Trigemina, Inc. develops drugs to control pain and migraine headache. Its platform is based on proprietary formulations of oxytocin, a naturally-occurring hormone, delivered through nasal-cerebral pathways for the treatment of a large spectrum of chronic and acute neurological disorders. The company was founded by David C. Yeomans in 2006 and is headquartered in Moraga, CA.

Excalibur Fund Managers Ltd (Excalibur) is a venture capital firm founded in 1996 by Christopher Evans. The firm is headquartered in London, United Kingdom.

Part of Ernst & Young Global Ltd., Arthur Andersen (UK) is a British company that provides accounting services. The company is based in Reading, UK.

BPC Plasma, Inc. manufactures pharmaceutical products. It offers the hyper immunoglobulin Nabi-HB, a key product used in the prevention of hepatitis B. The company was established in 2007 and is headquartered in Boca Raton, FL.

Part of Eli Lilly & Co., Lilly Deutschland GmbH is a pharmaceutical company based in Bad Homburg, Germany. The German company manufactures pharmaceutical products. The company was founded in 1960 by Eli Lilly. The CEO is Kadir Tepebasi.

Part of Ferring Holding SA, FKD Therapies Oy is a Finnish pharmaceutical company that manufactures and markets products for cancer treatment. The company is based in Kuopio, Finland. FKD Therapies was acquired by Ferring International Center SA on June 01, 2014.

Part of Ferring Holding SA, Finvector Vision Therapies Ltd. is a British pharmaceutical company that manufactures and markets products for cancer treatment. The company is based in Chinnor, UK. Finvector Vision Therapies was acquired by Ferring International Center SA on June 01, 2014.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

Part of Ferring Holding SA, Ferring Holding, Inc. is a company that manufactures and sells pharmaceuticals. The company is based in Parsippany, NJ.

NavBio AG provides business and management consulting services.

Semdor Pharma Group GmbH is a German pharmaceutical company that specializes in narcotics and medical cannabis. With the merger of Cannamedical Pharma and PS Pharma, it is the only full-service pharmaceutical narcotics company in Germany that has its own medical cannabis brand and sales team. Semdor Pharma Group is the leading pharmaceutical company for narcotics and medical cannabis in Germany.

IDT Biologika GmbH manufactures and distributes vaccines and biopharmaceuticals for the protection of human and animal health. The firm offers development services and manufacturing facilities for clinical phase I to III as well as commercial supplies for viral and bacterial human and animal health vaccines. The company was founded on July 1, 1921 and is headquartered in Dessau-Rosslau, Germany.